CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM079827
035-os BibID:(cikkazonosító)AS24-060
Első szerző:Árokszállási Tamás (neurológus)
Cím:Hemostasis biomarkers in the prognosis of non-traumatic intracerebral hemorrhage / T. Arokszallasi, Z. Bagoly, K. Fekete, I. Fekete, I. Szegedi, M. Andrejkovics, J. Toth, L. Csiba
Dátum:2019
Megjegyzések:Background and Aims: Non-traumatic intracerebral hemorrhage (ICH) accounts for 10?15% of all strokes and results in higher rate of mortality as compared to ischemic strokes. In the IRONHEART study we aimed to find potential hemostasis biomarkers with prognostic value in patients with ICH. Methods: In this prospective, observational study, 183 acute stroke patients and 140 healthy controls were included. Patients were grouped: 51 primary ICH patients (PICH), 118 acute ischemic stroke patients who underwent thrombolysis without hemorrhagic events (AIS), 13 patients with AIS who suffered hemorrhagic complications after intravenous thrombolysis (AIS-ICH). On admission, CT angiography, detailed clinical and laboratory investigations were performed. The following hemostasis measurements were carried out from blood samples: hemostasis screening tests, von Willebrand factor (VWF) antigen, factor XIII (FXIII), plasminogen and a2 antiplasmin activity, D-dimer. Patients were followed for 90 days, long term outcomes were defined using the modified Rankin Scale. Results: VWF level was significantly higher in all patient groups as compared to controls. VWF levels were significantly higher in patients with worse long-term outcomes (mRS>3) in all patient cohorts. FXIII activity was significantly elevated in the PICH group as compared to controls and to both AIS groups. FXIII activity in the lowest quartile was associated with a significant risk of mortality in the PICH group (OR: 9.9; 95%CI:1.6- 61.6, p ? 0.015). Among fibrinolytic markers, only D-dimer showed association with worse long-term outcomes (mRS>3). Conclusions: VWF antigen, FXIII activity and D-dimer could serve as biomarkers of long-term outcomes in PICH patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
haemorrhage
Megjelenés:European Stroke Journal. - 4 : Suppl. 1 (2019), p. 449. -
További szerzők:Bagoly Zsuzsa (1978-) (orvos) Fekete Klára (1978-) (neurológus) Fekete István (1951-) (neurológus, pszichiáter) Szegedi István (1992-) (orvos) Andrejkovics Mónika (1967-) (klinikai szakpszichológus, neuropszichológus, pszichoterapeuta) Tóth J. Csiba László (1952-) (neurológus, pszichiáter)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
NKFI-K120042
NKFI
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM079829
035-os BibID:(cikkazonosító)AS05-056
Első szerző:Fekete Klára (neurológus)
Cím:Predictors of long-term outcome in patients with basilar artery occlusion : a single center study / K. Fekete, J. Toth, H. Mate, M. Sandor, H. Toth, L. Csiba, I. Fekete
Dátum:2019
Megjegyzések:Background and Aims: Basilar artery occlusion (BAO) is a fatal disease despite recanalization techniques and limited data is available of the factors predicting outcome. Methods: Data of 100 patients treated with BAO was collected prospectively between 2004 and 2018. Risk factors, neurological status, outcome (case fatality, 3-months-mRS, one-year-survival); cranial CT (posterior circulation ASPECT score), result of CT angiography; and the treatment modality was given. Results: Average age was 64.9 13.7 years, 54% male. The most remarkable risk factor was previous stroke (29%), 55% of it vertebrobasilar (58% mortality). The onset to treatment time was 4.23 2.85 hours. The pc-ASPECT score was 10 in 67%, 7 points 33%. BAO was in the proximal part in 17%, in half in 20%, total in 21% and only the top in 42%; respectively within its group the mortality was 53%, 45%, 62%, 38%. Intravenous thrombolysis happened in 43%, intraarterial in 27%, combined therapy in 18% and 12% was treated conservatively. Case fatality within the treatment group was respectively: 48.8%, 55.5%, 33.3%, and 66.6% (p ? 0.8). Symptomatic haemorrhage was not different among the recanalization groups (p ? 0.83). Total or partial recanalization was achieved in 39%. There was a favourable trend in the recanalization rate of intraarterial and combined groups (p ? 0.4). At 3 months 23% had mRS 0?2, 3?5 42%, 58% were dead. At one year 26% was alive. Conclusions: The top occlusion of the BA, combined therapy may influence favourably the outcome. Among the risk factors previous VB stroke has a high impact. Trial registration number: N/A
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
haemorrhage
Megjelenés:European Stroke Journal. - 4 : Suppl. 1 (2019), p. 740. -
További szerzők:Tóth Judit (1964-) (radiológus) Máté H. Sándor Mária (1979-) (etnográfus) Tóth H. Csiba László (1952-) (neurológus, pszichiáter) Fekete István (1951-) (neurológus, pszichiáter)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM079833
Első szerző:Neumann J.
Cím:Diabetes mellitus and previous ischemic stroke in stroke thrombolysis : analysis of sitseast registry data / J. Neumann ,P. Kadlecová, A. Tomek, A. Kobayashi, Z. Gdovinova, V. Svigelj, K. Fekete, J. Kõrv, D. Jatuzis, R. Mikulík
Dátum:2016
Megjegyzések:Background: The European drug license for alteplase and current recommendations for ischemic stroke excludes from intravenous thrombolysis (IVT) patients with diabetes mellitus and previous ischemic stroke (DM ? pIS positive). Our aim was to evaluate safety and effectiveness of IVT in stroke patients with diabetes mellitus and previous ischemic stroke. Methods: We analyzed the data from the register SITSEAST between January 2002 and August 2013. DM ? pIS positive and DM ? pIS negative groups of patients were compared with respect to safety (symptomatic intracerebral hemorrhage [sICH]) and efficacy (modified Rankin scale [mRS]). Adjustment for baseline difference was performed with general estimating equation. Results: Of 12888 patients treated with IVT, 465 (4%) had DM ? pIS. DM ? pIS positive group had more severe ischemic stroke (median NIHS score 12 versus 11) and less frequently prestroke mRS 0?1 (70% versus 89%, P < 0,001) as compared to DM ? pIS negative patients. DM ? pIS positive patients had significantly lower adjusted odds to achieve mRS 0?1 (OR 0.69; 95% CI: 0.51?0.94) but not functional independence at 3 months (mRS 0?2, OR 0.75; 95% CI: 0.48?1.17). Adjusted odds for death (OR 1.32; 95% CI: 0.96?1.82) or disability was not significantly increased. No association between sICH and DM ? pIS was found (e.g. for MOST definition of ICH, OR was 1.73; 95% CI: 0.88?3.39). Conclusions: Patients with diabetes mellitus and previous ischemic stroke do not have increased risk of SICH, death or disability, but achieve less favorable outcome. Patients with diabetes mellitus and previous ischemic stroke should not be excluded from thrombolytic treatment.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
stroke
Megjelenés:European Stroke Journal. - 1 : Suppl. 1 (2016), p. 591. -
További szerzők:Kadlecova, Pavla Tomek, A. Kobayashi, Anna Gdovinova, Zuzana Švigelj, Victor Fekete Klára (1978-) (neurológus) Kõrv, Janika Jatuzis, Dalius Mikulík, Robert
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM079830
Első szerző:Orbán-Kálmándi Rita Angéla (klinikai laboratóriumi kutató)
Cím:The use of ex vivo clot lysis assay for predicting outcomes in acute ischemic stroke patients who underwent intravenous thrombolysis / R. Kálmándi, I. Szegedi, I. Fekete, K. Fekete, F. Sarkady, L. Varga, L. Csiba, Z. Bagoly
Dátum:2019
Megjegyzések:Background and Aims: The outcome of intravenous thrombolysis using recombinant tissue plasminogen activator (rtPA) is favorable in only 33?35% of acute ischemic stroke (AIS) patients. We tested whether an ex vivo clot-lysis assay performed before thrombolysis might predict therapy outcomes. Methods: Blood samples of 139 consecutive AIS patients, who underwent intravenous thrombolysis, were taken before thrombolysis. Plateletpoor-plasma was clotted using recombinant tissue factor, then lysis was induced with rtPA. Clot formation and lysis was monitored by turbidimetry in real time. In order to test the impact of neutrophil extracellular traps on lysis, assays were also performed in the presence of cell-freeDNA and histone. Stroke severity was determined by NIHSS on admission. Short- and long-term outcomes were defined at 7 days and 3 months post-event according to the change in NIHSS and by the modified Rankin Scale, respectively. Results: The median time to reach 50% lysis (50%CLT) was 47.3 (IQR:35.0-64.0) min in the total cohort, and became significantly prolonged in the presence of DNA and histone. A dose-response relationship was observed between stroke severity and 50%CLT. Patients with favorable short-term outcome had significantly shorter 50%CLT in the presence of DNA and histone as compared to patients with worse outcomes (median:50.6 (IQR:36.8-70.5) min vs. 62.0 (IQR:45.0-74.7) min; p < 0.05). Long-term outcomes and occurrence of post-lysis hemorrhage showed no association with clot-lysis assay results. 742 European Stroke Journal 4(1S) Conclusions: Clot-lysis assay using plasma of AIS patients taken before thrombolysis might be useful to predict short-term outcomes, but showed no association with hemorrhagic complications and long-term outcomes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
haemorrhage
Megjelenés:European Stroke Journal. - 4 : Suppl. 1 (2019), p. 742-743. -
További szerzők:Szegedi István (1992-) (orvos) Fekete István (1951-) (neurológus, pszichiáter) Fekete Klára (1978-) (neurológus) Sarkady Ferenc (1982-) (laboratóriumi analitikus) Varga L. Csiba László (1952-) (neurológus, pszichiáter) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
NKFI-K120042
NKFI
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM079828
035-os BibID:(cikkazonosító)AS24-058
Első szerző:Szegedi István (orvos)
Cím:The association of plasminogen activator inhibitor-1 (pai-1) 4g/5g polymorphism with the risk and prognosis of intracerebral hemorrhage / I. Szegedi, T. Arokszallasi, I. Fekete, K. Fekete, A. Nagy, F. Sarkady, E. G. Székely, K. R. Czuriga-Kovacs, E. Berenyi, Z. Bagoly, L. Csiba
Dátum:2019
Megjegyzések:Background and Aims: Non-traumatic intracerebral hemorrhage accounts for 10?15% of all strokes, but has much higher mortality than acute ischemic stroke (AIS). Plasminogen activator inhibitor-1 (PAI-1) is a natural inhibitor of fibrinolysis that protects against bleeding. PAI-1 5G/ 5G genotype is associated with lower PAI-1 levels, thus we hypothesized that it could be associated with the risk and outcome of intracerebral hemorrhage. Methods: Three populations were included in the study: 51 patients with primary intracerebral haemorrhage (PICH), 13 patients with AIS who suffered hemorrhagic transformation after intravenous thrombolysis (AIS-ICH), and 118 AIS patients without hemorrhagic events (AIS). PAI-1 4G/5G polymorphism was determined in all patients. Clinical data was registered on admission and day 7 post-event. Short-term outcome was defined according to NIHSS change at 7 days. Long-term outcome was measured by the modified Rankin Scale at 3 months. Results: The presence of PAI-1 5G allele was significantly more frequent in the AIS-ICH group as compared to the AIS and PICH cohorts and a population control cohort. PAI-1 4G/5G polymorphism had no effect on stroke severity or short-term outcome in either groups. In a binary backward logistic regression model including age, gender, BMI, NIHSS on admission, hypertension, hyperlipidaemia it was revealed that PAI-1 5G/5G genotype confers an independent, significant risk for post-lysis intracranial hemorrhage (OR:4.75, 95%CI:1.18-19.06, p ? 0.028). PAI-1 4G/5G polymorphism had no influence on mortality and long-term outcome in the studied patient cohorts. Conclusions: PAI-1 5G/5G genotype confers an independent, significant risk for post-lysis intracerebral haemorrhage.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
haemorrhage
Megjelenés:European Stroke Journal. - 4 : Suppl. 1 (2019), p. 470. -
További szerzők:Árokszállási Tamás (1988-) (neurológus) Fekete István (1951-) (neurológus, pszichiáter) Fekete Klára (1978-) (neurológus) Nagy A. Sarkady Ferenc (1982-) (laboratóriumi analitikus) Székely Edina Gabriella Czuriga-Kovács Katalin Réka (1981-) (neurológus) Berényi Ervin (1964-) (radiológus) Bagoly Zsuzsa (1978-) (orvos) Csiba László (1952-) (neurológus, pszichiáter)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
NKFI-K120042
NKFI
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM079857
035-os BibID:(cikkazonosító)AS08-015
Első szerző:Tsivgoulis, Georgios
Cím:Intravenous thrombolysis for patients with in-hospital stroke onset : propensity-matched analysis from the SITS-EAST registry / G. Tsivgoulis, A. H. Katsanos, P. Kadlecova, A. Czlonkowska, A. Kobayashi, M. Brozman, V. Švigelj, L. Csiba, K. Fekete, J. Kõrv, V. Demarin, A. Vilionskis, D. Jatuzis, Y. Krespi, C. Liantinioti, S. Giannopoulos, R. Mikulik
Dátum:2017
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
stroke
Megjelenés:European Stroke Journal. - 2 : Suppl. 1 (2017), p. 71. -
További szerzők:Katsanos, Aristeidis H. Kadlecova, Pavla Czlonkowska, A. Kobayashi, Adam Brozman, Miroslav Švigelj, Victor Csiba László (1952-) (neurológus, pszichiáter) Fekete Klára (1978-) (neurológus) Kõrv, Janika Demarin V. Vilionskis, Aleksandras Jatuzis, Dalius Krespi, Yakup Liantinioti, Chrissoula Giannopoulos, Sotirios Mikulík, Robert
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.